arrow
C

Claire Gervais

AP-HP
H指数:24
被引数:1,691

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel – A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials

集成预后评分在卡巴他赛治疗转移性去势抵抗性前列腺癌中的应用——CABASTY事后分析并由两项国际前瞻性III期试验验证

2026-04-220
OAAI
Feasibility of Standard Versus Fractionated Carboplatin-Paclitaxel in Older Adults with Ovarian Cancer: A Retrospective Study

标准与分次卡铂-紫杉醇方案在老年卵巢癌患者中的可行性:一项回顾性研究

2025-12-050
PRE
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
2024-07-180
OAAI
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers
2022-06-255
OA
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
2021-11-0110
OAAI
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study
2020-09-010
OAAI
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

在CERTIM泛癌症队列中,肿瘤炎症特征 (TIS) 与anti-PD-1治疗益处相关

2019-11-04106
OAAI
Prediction of the efficacy of nivolumab using resting energy expenditure in metastatic non-small cell lung cancer (mNSCLC) patients
2018-07-010
PRE